Case Report: Sustained Response to TMEp-CI-M Platform in Refractory SCLC

A single-case report from figshare details a 60-year-old male patient with PD-L1-negative extensive-stage small-cell lung cancer and brainstem metastasis. The patient was treated with the TMEp-CI-M platform, achieving no evidence of disease for over 20 months. Authored by Yating Wu and last updated on 2026-06-01, the dataset is a 15.8 KB document licensed under CC-BY-4.0.

Use Cases

• Analyze the efficacy of a sequential TMEp-CI-M regimen based on the detailed treatment protocol described.
• Study biomarker response in immunotherapy based on the reported ProGRP level normalization from 1803 pg/mL to 23.71 pg/mL.
• Investigate long-term outcomes in brainstem metastasis based on the reported over 20 months of disease-free survival.
• Review adverse event profiles for combined radiotherapy, chemotherapy, and immunotherapy based on the mention of Grade 1 hypothyroidism.

Strengths

• Provides a detailed clinical timeline and treatment response for a rare condition (brainstem metastasis from SCLC).
• Includes specific biomarker measurements, such as ProGRP levels decreasing from 1803 pg/mL to 23.71 pg/mL.
• Reports a concrete clinical outcome of over 20 months of disease-free survival.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is a single-case report (15.8 KB), representing a very limited sample size.

Provenance

Source

figshare

Collection Method

Likely contains a detailed clinical case report authored by Yating Wu.

Freshness

Last updated 2026-06-01 05:18:37; freshness should be verified.